Aquapheresis represents a feasible non-pharmacological treatment option for fluid-overloaded heart failure patients, particularly those resistant to loop diuretics.
Answers are grounded in this paper and cite their sources.
May support aquapheresis evaluation in diuretic-resistant HF; leaves open the need for randomized trials before adoption.
Heart failure is one of the most common causes of hospital emergency admissions (5%), re-admissions and bed day occupancy, and these rates are predicted to increase in the future. Of all heart failure admissions, 90% are due to fluid overload. Currently, loop diuretics are the ‘hallmark’ treatment, however some patients become resistant to diuretic therapy over time and diuretics have a high rate of adverse effects. Considering the large number of patients, increased morbidity, mortality rates and resource use, current management strategies are not optimal: new therapies are required and should be evaluated thoroughly. Aquapheresis (AQ) is a non-pharmacological procedure that removes excess water and sodium from the blood via a filter using a simplified ultrafiltration (UF) device. This article discusses AQ as a treatment option. AQ is a relatively new therapy in the UK and has some advantages over conventional therapy. In particular, patients can be treated with AQ in a cardiology setting, this may allow rapid removal of excess fluid and earlier discharge. Close consultant supervision and input is required with dedicated nursing staff managing the patient. A formal UK health economic analysis is required. AQ provides a feasible, additional treatment option for patients with heart failure in the UK, which are significantly limited at present.
No takes yet. Share an insight, caveat, or question.
Wick et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: